Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Subscribe To Our Newsletter & Stay Updated
